دورية أكاديمية
Study of the resistome of human microbial communities using a targeted panel of antibiotic resistance genes in COVID-19 patients
| العنوان: | Study of the resistome of human microbial communities using a targeted panel of antibiotic resistance genes in COVID-19 patients |
|---|---|
| المؤلفون: | Oleg O. Yanushevich, Igor V. Maev, Natella I. Krikheli, Oleg V. Levchenko, Julia S. Galeeva, Elizaveta V. Starikova, Dmitry N. Andreev, Philipp S. Sokolov, Aleksei K. Fomenko, Mikhail K. Devkota, Nikolai G. Andreev, Andrew V. Zaborovsky, Vladimir V. Evdokimov, Sergey V. Tsaregorodtsev, Elena N. Ilina, Vadim M. Govorun, Petr A. Bely, Elena A. Sabelnikova, Aleksandr A. Solodov, Sergei V. Cheremushkin, Rafik I. Shaburov, Anastasia L. Kebina |
| المصدر: | Терапевтический архив, Vol 95, Iss 12, Pp 1103-1111 (2023) |
| بيانات النشر: | "Consilium Medicum" Publishing house, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Medicine |
| مصطلحات موضوعية: | coronavirus, covid-19, sars-cov-2, antibiotic resistance, disease severity, gene, resistome, sequencing, efflux pump, Medicine |
| الوصف: | Aim. To study overall drug resistance genes (resistome) in the human gut microbiome and the changes in these genes during COVID-19 in-hospital therapy. Materials and methods. A single-center retrospective cohort study was conducted. Only cases with laboratory-confirmed SARS-CoV-2 RNA using polymerase chain reaction in oro-/nasopharyngeal swab samples were subject to analysis. The patients with a documented history of or current comorbidities of the hepatobiliary system, malignant neoplasms of any localization, systemic and autoimmune diseases, as well as pregnant women were excluded. Feces were collected from all study subjects for subsequent metagenomic sequencing. The final cohort was divided into two groups depending on the disease severity: mild (group 1) and severe (group 2). Within group 2, five subgroups were formed, depending on the use of antibacterial drugs (ABD): group 2A (receiving ABD), group 2AC (receiving ABD before hospitalization), group 2AD (receiving ABD during hospitalization), group 2AE (receiving ABD during and before hospitalization), group 2B (not receiving ABD). Results. The median number of antibiotic resistance (ABR) genes (cumulative at all time points) was significantly higher in the group of patients treated with ABD: 81.0 (95% CI 73.8–84.5) vs. 51.0 (95% CI 31.1–68.4). In the group of patients treated with ABD (2A), the average number of multidrug resistance genes (efflux systems) was significantly higher than in controls (group 2B): 47.0 (95% CI 46.0–51.2) vs. 21.5 (95% CI 7.0–43.9). Patients with severe coronavirus infection tended to have a higher median number of ABR genes but without statistical significance. Patients in the severe COVID-19 group who did not receive ABD before and during hospitalization also had more resistance genes than the patients in the comparison group. Conclusion. This study demonstrated that fewer ABR genes were identified in the group with a milder disease than in the group with a more severe disease associated with more ABR genes, with the following five being the most common: SULI, MSRC, ACRE, EFMA, SAT. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | Russian |
| تدمد: | 0040-3660 2309-5342 00403660 |
| Relation: | https://ter-arkhiv.ru/0040-3660/article/viewFile/626323/142202; https://doaj.org/toc/0040-3660; https://doaj.org/toc/2309-5342 |
| DOI: | 10.26442/00403660.2023.12.202490 |
| URL الوصول: | https://doaj.org/article/1448ee50813845c28918717bc5b5a46b |
| رقم الأكسشن: | edsdoj.1448ee50813845c28918717bc5b5a46b |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 00403660 23095342 |
|---|---|
| DOI: | 10.26442/00403660.2023.12.202490 |